• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    6/19/24 4:30:52 PM ET
    $ASLN
    $BIMI
    $BIOL
    $CSTL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Pharmaceuticals
    Health Care
    Get the next $ASLN alert in real time by email

    Gainers

    • Nexalin Technology (NASDAQ:NXL) stock increased by 48.1% to $1.54 during Wednesday's after-market session. The company's market cap stands at $11.4 million.
    • Tempest Therapeutics (NASDAQ:TPST) stock moved upwards by 40.0% to $3.99. The market value of their outstanding shares is at $88.6 million.
    • ASLAN Pharma (NASDAQ:ASLN) stock increased by 18.51% to $0.37. The market value of their outstanding shares is at $8.3 million.
    • Talphera (NASDAQ:TLPH) shares increased by 15.18% to $0.9. The company's market cap stands at $15.2 million.
    • Geovax Labs (NASDAQ:GOVX) stock rose 13.15% to $2.15. The market value of their outstanding shares is at $5.4 million.
    • SAB Biotherapeutics (NASDAQ:SABS) stock moved upwards by 8.94% to $2.8. The market value of their outstanding shares is at $25.8 million.

    Losers

    • Biolase (NASDAQ:BIOL) stock fell 15.5% to $0.11 during Wednesday's after-market session. The company's market cap stands at $3.6 million.
    • Castle Biosciences (NASDAQ:CSTL) shares declined by 10.77% to $19.82. The company's market cap stands at $547.1 million.
    • Mustang Bio (NASDAQ:MBIO) shares fell 10.59% to $0.76. The company's market cap stands at $21.4 million.
    • Evaxion Biotech (NASDAQ:EVAX) stock decreased by 9.53% to $2.47. The market value of their outstanding shares is at $13.3 million.
    • Soligenix (NASDAQ:SNGX) shares declined by 8.5% to $3.88. The company's market cap stands at $3.8 million.
    • BIMI Holdings (NASDAQ:BIMI) stock declined by 7.41% to $1.25. The company's market cap stands at $17.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ASLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASLN
    $BIMI
    $BIOL
    $CSTL

    CompanyDatePrice TargetRatingAnalyst
    SAB Biotherapeutics Inc.
    $SABS
    4/3/2026$13.00Buy
    Rodman & Renshaw
    SAB Biotherapeutics Inc.
    $SABS
    4/2/2026$13.00Buy
    Rodman & Renshaw
    GeoVax Labs Inc.
    $GOVX
    2/19/2026Buy → Hold
    D. Boral Capital
    Evaxion A/S
    $EVAX
    2/19/2026$10.00Buy
    Maxim Group
    Tempest Therapeutics Inc.
    $TPST
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    SAB Biotherapeutics Inc.
    $SABS
    12/19/2025$15.00Buy
    Guggenheim
    SAB Biotherapeutics Inc.
    $SABS
    9/17/2025$7.00Outperform
    Leerink Partners
    SAB Biotherapeutics Inc.
    $SABS
    5/14/2025$10.00Buy
    H.C. Wainwright
    More analyst ratings

    $ASLN
    $BIMI
    $BIOL
    $CSTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Angotti Vincent J.

    4 - TALPHERA, INC. (0001427925) (Issuer)

    4/3/26 6:10:17 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Asadorian Raffi

    4 - TALPHERA, INC. (0001427925) (Issuer)

    4/3/26 6:09:19 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Aslam Shakil

    4 - TALPHERA, INC. (0001427925) (Issuer)

    4/3/26 6:08:02 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $BIMI
    $BIOL
    $CSTL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

    HyBryte™ demonstrates more rapid and robust treatment response compared toValchlor® during 12-week treatment coursePRINCETON, N.J., April 2, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the positive results of its comparability study evaluating HyBryte™ (synthetic hypericin) versus Valchlor® (mechlorethamine) for the treatment of cutaneous T-cell lymphoma (CTCL) have been published in Oncology and Therapy. 

    4/2/26 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

    Upcoming high-impact milestones include interim analysis in Q2 2026 and top-line results in H2 2026 from HyBryte™ trialPRINCETON, N.J., March 31, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2025. "We are entering a pivotal year with several high-impact clinical and regulatory milestones across our rar

    3/31/26 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Reports Year End 2025 Financial Results and Provides Business Update

    Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today reported financial results for the year ended December 31, 2025, and provided a corporate update. "2025 was a transformative year for Tempest as we stre

    3/30/26 9:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $BIMI
    $BIOL
    $CSTL
    SEC Filings

    View All

    SEC Form D filed by Tempest Therapeutics Inc.

    D - Tempest Therapeutics, Inc. (0001544227) (Filer)

    4/3/26 2:28:03 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Soligenix Inc.

    EFFECT - SOLIGENIX, INC. (0000812796) (Filer)

    4/3/26 12:15:07 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Soligenix Inc.

    EFFECT - SOLIGENIX, INC. (0000812796) (Filer)

    4/3/26 12:15:04 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $BIMI
    $BIOL
    $CSTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on SAB BIO with a new price target

    Rodman & Renshaw initiated coverage of SAB BIO with a rating of Buy and set a new price target of $13.00

    4/3/26 10:44:59 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rodman & Renshaw initiated coverage on SAB BIO with a new price target

    Rodman & Renshaw initiated coverage of SAB BIO with a rating of Buy and set a new price target of $13.00

    4/2/26 8:11:56 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GeoVax Labs downgraded by D. Boral Capital

    D. Boral Capital downgraded GeoVax Labs from Buy to Hold

    2/19/26 8:44:06 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $BIMI
    $BIOL
    $CSTL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Angotti Vincent J. covered exercise/tax liability with 12,738 shares and bought $85,587 worth of shares (105,364 units at $0.81), increasing direct ownership by 19% to 577,395 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/20/26 8:28:48 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Aslam Shakil bought $28,430 worth of shares (35,000 units at $0.81), increasing direct ownership by 73% to 83,178 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/20/26 8:27:03 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Engineering Officer Dasu Badri N covered exercise/tax liability with 3,127 shares and bought $28,430 worth of shares (35,000 units at $0.81), increasing direct ownership by 76% to 73,884 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/20/26 8:25:17 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $BIMI
    $BIOL
    $CSTL
    Leadership Updates

    Live Leadership Updates

    View All

    Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas

    FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time. The event will take place at the Company's new campus located at 1500 West Parkwood Avenue in Friendswood, Texas, and will bring together employees, community partners and other invited guests to commemorate the completion of the purpose-built facility. Local, state and national elected officials are expected to join the event, underscoring the significance of Castle's i

    3/3/26 4:30:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

    David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D. to its Board of Directors as Chair of the Board and the appointment of Rita Jain, M.D., as an independent director, both effective immediately. "We are excited to welcome Dr. David Zaccardelli and Dr. Rita Jain to our Board of Directors. I, along with the rest of our Board, am confi

    1/7/26 8:00:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

    HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. ("Carmi Masha"), a leading Israeli medical device distributor, to market and sell Nexalin's Gen-2 Console ("SYNC"), 15 milliamp (mA), non-invasive frequency-based neurostimulation device throughout Israel. This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin's Gen-2 SYNC device in Israel for the treatment of a var

    11/13/25 9:15:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ASLN
    $BIMI
    $BIOL
    $CSTL
    Financials

    Live finance-specific insights

    View All

    Evaxion plans to file 2025 annual report later today

    COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will slightly delay the filing and publication of its 2025 annual report, planned before opening of Nasdaq CM today, due to unforeseen technical issues with external vendors.   The report has been finalized as planned and will be filed and published as soon as possible. The technical issues relate to regulatory filing demands and have nothing to do with the report itself.  As a consequence of the technical delay, the conference call and webcast planned for today will be moved to tomorrow: Friday March 6 at 8.30 E

    3/5/26 8:02:13 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial

    Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sitesCompany to host a virtual investor and analyst event on March 23 at 11:00 am ET featuring nephrologists, Dr. Blaithin McMahon and Dr. Joao TeixeiraSAN MATEO, Calif., March 2, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced 50% patient enrollment of the NEPHRO-CRRT clinical trial."Over the course of 2025, with agreement from the FDA, we implemented significant changes to the NEPHRO CRRT clinical tr

    3/2/26 8:30:00 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evaxion to announce business update and full year 2025 financial results on March 5, 2026

    COPENHAGEN, Denmark, March 2, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its full year 2025 financial results on Thursday March 5, 2026, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be acces

    3/2/26 8:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASLN
    $BIMI
    $BIOL
    $CSTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GeoVax Labs Inc.

    SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

    11/14/24 5:10:48 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

    SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    11/14/24 4:40:39 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mustang Bio Inc.

    SC 13G/A - MUSTANG BIO, INC. (0001680048) (Subject)

    11/14/24 4:21:44 PM ET
    $MBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care